LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

2.97 -1.66

Overview

Share price change

24h

Current

Min

2.94

Max

2.99

Key metrics

By Trading Economics

Income

-15M

-40M

Sales

8.2M

50M

Profit margin

-80.43

Employees

435

EBITDA

-19M

-42M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+34.23% upside

Dividends

By Dow Jones

Next Earnings

11 maj 2026

Market Stats

By TradingEconomics

Market Cap

37M

1.2B

Previous open

4.63

Previous close

2.97

News Sentiment

By Acuity

50%

50%

147 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 mar 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mar 2026, 23:50 UTC

Market Talk

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

22 mar 2026, 23:49 UTC

Market Talk
Major News Events

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

22 mar 2026, 23:49 UTC

Market Talk
Major News Events

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

22 mar 2026, 23:49 UTC

Market Talk
Major News Events

Global Forex and Fixed Income Roundup: Market Talk

22 mar 2026, 23:41 UTC

Market Talk
Major News Events

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

22 mar 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

22 mar 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

22 mar 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

22 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Participated in Aurum Resources Equity Raising

22 mar 2026, 22:54 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

22 mar 2026, 22:22 UTC

Market Talk
Major News Events

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

22 mar 2026, 21:25 UTC

Market Talk
Major News Events

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

22 mar 2026, 21:22 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

22 mar 2026, 21:21 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

22 mar 2026, 21:21 UTC

Market Talk

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

22 mar 2026, 21:21 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

34.23% upside

12 Months Forecast

Average 4 USD  34.23%

High 5 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

147 / 350 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat